TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Response levels (WOMAC 50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum thromboxane B2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximal platelet aggregation in response to collagen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Closure time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cumulative incidence of recurrent upper GI bleeding
Endpoint domain: Mortality/survival
Primary endpoint: combined two-year rate of cardiovascular death or non-fatal myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Safety of injectable AS
Endpoint domain: Adverse events/effects
Primary endpoint: Mean elimination half-lives of AS and DHA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak concentration (C(max)) of AS and DHA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood eosinophils levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Sputum lymphocytes levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: symptomatic recurrent VTE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Improvement in participant understanding of nutrient profile
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Identification of nutrients in excess
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visibility of warning labels (WLs)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Self-reported sleep latency
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Enhancing lesion/scan ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in lymphocyte GSH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Development of fissure caries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in total pain hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in high- and medium-intensive pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hypothermia rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: shivering rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neurodevelopmental improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Multiple organ dysfunction syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interleukin-6 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Muscle strength (1RM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cross-sectional area (CSA) of the quadriceps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Transition between depression and anxiety symptom classes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Raised total IgE levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sensitization to at least one allergen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Micronutrient intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Axial length of eyeball
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hematocrit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: improvement in functional class and walk distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of ventilator alarms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality rate in ICU
Endpoint domain: Mortality/survival
Primary endpoint: Infants weaned by 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absorption of magnesium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Absorption of calcium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Absorption of sulphate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Arterial oxygen saturation (SaO2) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypotension (systolic blood pressure less than 100 mm Hg)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of eligible cases receiving thrombolytic therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: incidence of first non-enteric peritonitis
Endpoint domain: Mortality/survival
Primary endpoint: Aix75
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bleeding volume during the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: graft take
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: comfort level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Objective cure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Subjective cure rates by satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Suppression of the oscillatory component of venous reflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in Tumor Necrosis Factor‐α (TNFα)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decrease in Interferon gamma‐induced Protein 10 (IP‐10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: referral for consideration of defibrillator implantation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: mean changes from baseline in total area of lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean changes from baseline in CNV area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean changes from baseline in total area CNV leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of ganglion
Endpoint domain: Mortality/survival
Primary endpoint: Medication use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative remission rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proteinuria (g/g Cr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Work satisfaction (SEWDR scores)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quality of life (QOL-AD scores)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: patient's experience of admission to a psychiatric hospital
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Common seborrheic keratosis (CSK) prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dermoscopy findings consistency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect size of psychological treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TNF-alpha secretion profile change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CMV infection development
Endpoint domain: Adverse events/effects
Primary endpoint: CMV disease development
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of ipsilateral breast cancer
Endpoint domain: Adverse events/effects
Primary endpoint: Cortisol output (AUCg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean decrease in HCV RNA at 48 hours post first dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Sensitivity in detecting early-stage lung cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive predictive value of lung cancer screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stage distribution of lung cancers diagnosed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Concordance levels between patients and therapists
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Resistance during treatment sessions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Detection and count of HITS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Transferability of acquired skill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kupperman score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bishop score changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Induction to active phase of labor interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Two consecutive >= 30% decreases in intact PTH from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma vasopressin (P(VP)) secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic knee loading deficits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of correct diagnosis at 4 hours after arrival
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: overall response rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of VPC-initiated episodes of VF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Predictive factor for death
Endpoint domain: Mortality/survival
Primary endpoint: Reduction of at least 20% in the oxygenation index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Unified Parkinson's Disease Rating Scale improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognition (visual episodic memory)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional competence (ABAS II‐Home Living skills)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Postarrival incremental change in troponin‐T at 72 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Positive skin reaction to prick test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Death or (re)infarction within 24 hours
Endpoint domain: Mortality/survival
Primary endpoint: development of new abscess and/or fistula
Endpoint domain: Adverse events/effects
Primary endpoint: recurrent disease in the follow-up period
Endpoint domain: Adverse events/effects
Primary endpoint: Urogenital schistosomiasis prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anesthesia induction compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: mean probing depths
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in AR-QOL (Δ PAQLQ[S] scores)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Decrease in body mass index z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fewer events of acute attacks of asthma
Endpoint domain: Adverse events/effects
Primary endpoint: Acceptable tracheal intubating conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blunting of pressor response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of respondents consenting to intervention based on postponement of hip fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: perceived benefits of preconception counseling
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: perceived support with reproductive health issues
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient agenda addressed
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: neutropenia rate
Endpoint domain: Adverse events/effects
Primary endpoint: Fibrin network permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: KPS score improving rate
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Bone resorption markers (NTx and Crosslaps)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: actual sleep time
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Gain in PAL (Probing Attachment Level)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Horizontal dimensions of furcation defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertical dimensions of furcation defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: children's growth at 18 months of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in mucosal irritation complaints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lumbar bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Prevalence of abnormal anal cytology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of bHSIL on biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of anal HPV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MIBG scintigraphic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: hs-TnT level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: maximal aerobic capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fractional absorption of alpha-tocopherol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residence time in liver kinetic pool A and plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distribution of plasma alpha-tocopherol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean stay in hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mean time to recovery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Signal power at 5 and 10 Hz
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sensitivity of diagnostic modalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Early Treatment of Diabetic Retinopathy Study letters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Choroidal neovascular membrane size decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ablation fluoroscopy time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Calcium risk ratio for histologically advanced neoplasms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Size and total number of oral ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing time for venous leg ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum venous pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: incidence of lidocaine leak
Endpoint domain: Adverse events/effects
Primary endpoint: mean lidocaine plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nighttime driving performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stroke or cardiovascular death
Endpoint domain: Mortality/survival
Primary endpoint: change in creatinine clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rhythmicity of sedation levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diurnal sedation achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delay in deterioration of health-related QOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: medication adherence behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: negative side effects and attitudes toward psychotropic medication
Endpoint domain: Adverse events/effects
Primary endpoint: anatomical recurrence of the apical compartment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pharyngeal pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight loss of 20% or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean percentage weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hamilton Depression Rating Scale (HAMD) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission rate
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Posterior Capsule Opacification (PCO) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nickel levels in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain in the first two postoperative weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrent Grade III haemorrhoids
Endpoint domain: Adverse events/effects
Primary endpoint: Average dose of propofol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Occurrence of stress fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Basal levels of [Ca](i) in platelets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: time to first progression
Endpoint domain: Mortality/survival
Primary endpoint: Specialty selection
Endpoint domain: Life impact
Endpoint subdomain: Career outcomes
Primary endpoint: Cancer-related mortality risk
Endpoint domain: Mortality/survival
Primary endpoint: General self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of detection of LAD, cardioembolic and undetermined causes of stroke or TIA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Inter-rater reliability of SPARKLE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-rater reliability of SPARKLE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfaction with infant feeding method
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: breastfeeding duration and exclusivity rates
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quality of life under therapy
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to tumour progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of patients with undetectable viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PC(20) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in heel pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: D28 cure rates defined as absence of parasitemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients reporting adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: IL-8 levels in aqueous
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IL-8 levels in vitreous
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PDGF-AA levels in vitreous
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Eight-year survival
Endpoint domain: Mortality/survival
Primary endpoint: Freedom from need for reoperation at 8 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Freedom from evolving aortic valve dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Achieving LDL-C target
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes